Heron Therapeutics, Inc.
NASDAQ:HRTXBiotechnology
Healthcare
$0.26 +3.74%
+$0.01 today
- Market cap
- $50.25M
- Beta
- 1.57
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.16
52W Low $0.38High $2.30
Volume 3.60M
Average 2.90M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$27.59M
FY 2025 · Annual
Investing Cash Flow
$16.01M
FY 2025 · Annual
-14.5% YoYFinancing Cash Flow
$14.43M
FY 2025 · Annual
+1434.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (220.68M) | (182.02M) | (110.56M) | (13.58M) | (20.2M) |
| Depreciation & Amortization | 3.02M | 2.89M | 2.9M | 2.49M | 2.31M |
| Deferred Income Tax | 1.63M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 46.85M | 42.98M | 32.85M | 12.96M | 10.34M |
| Change in Working Capital | (35.08M) | (10.51M) | 16.79M | (27.6M) | (31.88M) |
| Accounts Receivables | 6.35M | (16.55M) | (8.09M) | (18.74M) | (10.71M) |
| Inventory | (6.48M) | (6.19M) | 12.46M | (11.05M) | (31.05M) |
| Accounts Payables | 3.28M | (578K) | 15K | 8.47M | (2.72M) |
| Other Working Capital | (38.23M) | 12.81M | 12.4M | (6.28M) | 12.59M |
| Other Non-Cash Items | 904K | (251K) | (773K) | 3.2M | 11.83M |
| Operating Cash Flow | (203.35M) | (146.91M) | (58.79M) | (22.53M) | (27.59M) |
| Capital Expenditures | (3.02M) | (1.83M) | (1.55M) | (1.71M) | (317K) |
| Acquisitions (Net) | 32K | 227K | 13K | 27K | 0 |
| Purchases of Investments | (129.22M) | (145.68M) | (87.66M) | (103.09M) | (50.79M) |
| Sales of Investments | 164.94M | 143.96M | 107.19M | 123.48M | 67.01M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 98K |
| Investing Cash Flow | 32.73M | (3.32M) | 18M | 18.71M | 16.01M |
| Debt Repayment | 148.96M | 0 | 24.35M | 0 | 145.11M |
| Common Stock Issued | 7.07M | 75.06M | 29.76M | 940K | 19.32M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | (150M) |
| Financing Cash Flow | 156.03M | 75.06M | 54.11M | 940K | 14.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (14.6M) | (75.18M) | 13.31M | (2.88M) | 2.85M |
| Free Cash Flow | (206.38M) | (148.74M) | (60.33M) | (24.24M) | (27.91M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$20.2M
+ D&A$2.3M
+ Stock-Based Comp$10.3M
+ Deferred Tax$0
- Working Capital-$31.9M
+ Other Non-Cash$11.8M
= Operating Cash Flow-$27.6M
- Capex-$317.0K
= Free Cash Flow-$27.9M
Analysis
FY2025 free cash flow is -$27.9M. FCF conversion is 138.2% of net income. Operating cash flow was -$27.6M, with capex of -$317.0K. The largest bridge item is Working Capital at -$31.9M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 10, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| DEFA14A | DEFA14A filing | Nov 9, 2026 | |
| DEFA14A | DEFA14A filing | Nov 9, 2026 |
Does HRTX generate free cash flow?
Heron Therapeutics, Inc. (HRTX) generated -$27.91M of free cash flow in fiscal 2025.
How much operating cash flow does HRTX produce?
Operating cash flow was -$27.59M, before capital expenditures of $317,000.00.
Continue the stock analysis
Jump to another research area for this company.